Fierce Pharma September 30, 2024
After experiencing a series of ups and downs in recent years, the biopharma contracting business is gearing up for a rebound in 2025. That’s according to new research from CPHI Milan ahead of the group’s manufacturing conference next month.
As it stands, 49% of the CDMO industry is “highly positive” on contract services growth in the next 18 months, CPHI said in a release, citing new research pooling insights from 280 pharma companies.
The optimistic mood comes despite an uneven recovery in the biopharma industry after the pandemic. While funding has flowed to later-stage projects, early-stage assets continue to face a funding deficit, Gil Roth, president of the Pharma & Biopharma Outsourcing Association said in a statement.
“This means that...
Today's Sponsors
Today's Sponsor